Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
134 hedge funds and large institutions have $1B invested in Genomic Health, Inc. in 2018 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 37 reducing their positions, and 22 closing their positions.
27% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 37
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
1% less funds holding
Funds holding: 135 → 134 (-1)
8% less capital invested
Capital invested by funds: $1.09B → $1B (-$85.8M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$46.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$7.43M |
| 3 |
State Street
Boston,
Massachusetts
|
+$6.61M |
| 4 |
Renaissance Technologies
New York
|
+$5.66M |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tributary Capital Management
Omaha,
Nebraska
|
-$10.9M |
| 2 |
MFWM
Motley Fool Wealth Management
Alexandria,
Virginia
|
-$5.37M |
| 3 |
MFAM
Motley Fool Asset Management
Alexandria,
Virginia
|
-$4.51M |
| 4 |
First Manhattan
New York
|
-$3.79M |
| 5 |
CPA
Cowen Prime Advisors
New York
|
-$3.59M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
FHA
151
First Horizon Advisors
Memphis,
Tennessee
| – | -$31K | -890 | Closed |
|
|
TRCT
152
Tower Research Capital (TRC)
New York
| – | -$21K | -615 | Closed |
|
153
Pacer Advisors
Malvern,
Pennsylvania
| – | -$9K | -250 | Closed |
|
|
KJWM
154
Kiley Juergens Wealth Management
Olympia,
Washington
| – | -$3K | -100 | Closed |
|
|
GI
155
Gradient Investments
Arden Hills,
Minnesota
| – | -$1K | -17 | Closed |
|
GHDX Hedge Fund Activity: Q1 2018 in Review
134 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q1 2018, worth a combined $1B — down 7.9% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new GHDX positions and 22 closed out — a net gain of 3 holders — while 47 added to existing stakes and 37 trimmed.
The largest buyer was Ameriprise, adding an estimated $46.9M. The largest seller was Tributary Capital Management, exiting entirely with an estimated $10.9M sold.
- 134 institutional investors held Genomic Health, Inc. (GHDX) as of Q1 2018, down from 135 in Q4 2017.
- Funds reported $1B of Genomic Health, Inc. stock for Q1 2018, down 7.9% quarter-over-quarter.
- 25 funds opened new Genomic Health, Inc. positions in Q1 2018 and 22 closed out, a net change of +3 holders.
- The largest Genomic Health, Inc. buyer in Q1 2018 was Ameriprise, an estimated $46.9M added.
- The largest Genomic Health, Inc. seller in Q1 2018 was Tributary Capital Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2018.